Guided Therapeutics (GTHP) Liabilities and Shareholders Equity (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 3.92% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $4.1 million (down 23.05% YoY), and the FY2025 full-year result was $1.3 million, down 3.92% from the prior year.
• Liabilities and Shareholders Equity climbed to $1.3 million in Q4 2025, from $903000.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.9 million in Q3 2022 to a low of $903000.0 in Q3 2025.
• A 5-year average of $1.9 million and a median of $1.7 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 548.9% in 2021 and tumbled 51.51% in 2023, its largest moves.
• Tracing GTHP's Liabilities and Shareholders Equity over 5 years: stood at $2.0 million in 2021, then soared by 65.0% to $3.4 million in 2022, then slumped by 50.42% to $1.7 million in 2023, then declined by 17.44% to $1.4 million in 2024, then dropped by 3.92% to $1.3 million in 2025.
• Business Quant data shows GTHP's Liabilities and Shareholders Equity at $1.3 million in Q4 2025, $903000.0 in Q3 2025, and $940000.0 in Q2 2025.